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ABBREVIATIONS
APR  Abdominoperineal resection 
AR                  Anterior resection
CRM               Circumferential resection margin
CRC                Colorectal cancer 
ERUS              Endorectal Ultrasonography
FAP                 Familial adenomatous polyposis 
HNPCC           Hereditary non-polyposis colorectal cancer syndrome
IBD                  Inflammatory bowel disease 
LR                    Local recurrence 
TEM                Transanal endoscopic microsurgery
TME                Total mesorectal excision 
UICC               Union Internationelle Contre le Cancer 
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DEFINITIONS
pTNM classification system (rectal cancer) >1@
The TNM system describes the anatomical extent of the disease, based on: 
T     The extent of the primary tumour
N     The absence or presence of lymph node metastasis
M    The absence or presence of distant metastasis
TX    Primary tumour cannot be assessed 
T0     No evidence of primary tumour
Tis    Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1     Tumour invades submucosa
T2     Tumour invades muscularis propria 
T3     Tumour invades through muscularis propria into subserosa or perirectal fatty tissue 
T4     Tumour directly invades other organs or structures and/or perforates visceral
          peritoneum
NX    Regional lymph nodes cannot be assessed 
N0     No regional lymph node metastasis
N1     Metastasis in 1 to 3 regional lymph nodes 
N2     Metastasis in 4 or more regional lymph nodes 
MX   Distant metastasis cannot be assessed
M0    No distant metastasis
M1    Distant metastasis
Tumour stages (UICC) >1@ Dukes’ stages >1@
Stage 0    Tis, N0, M0 
Stage I     T1-2, N0, M0      A 
Stage II    T3-4, N0, M0      B 
Stage III   Any T, N1-2, M0      C 
Stage IV   Any T, Any N, M1      D 
R-stage (Residual tumour stage) >1@
R 0     No residual tumour
R 1     Microscopic residual tumour
R 2     Macroscopic residual tumour
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Circumferential resection margin (CRM)
The shortest distance (in mm) from the outermost part of the tumour or any malignant lymph
node to the resection margin.
Involved circumferential margin
CRM d 1 mm >2@.
Rectal adenoma
A rectal tumour involving the mucosa, not invading the submucosa, thus including Tis. 
Rectal cancer
The definition of rectal cancer according to tumour level (distance from anal verge to the 
lower border of the tumour, measured on rigid proctoscope) varies between 10 and 18 cm
from the anal verge >3@. In the present work only adenocarcinomas are included. In paper I all
tumours within 18 cm were included. In paper II all tumours within 15 cm, and in paper III 
and IV all tumours within 16 cm were included. 
Mesorectum
The fatty tissue surrounding the rectum, containing rectal vessels and lymphatic tissue, 
enveloped by the mesorectal fascia >4@.
Total mesorectal excision (TME)
TME is defined as a rectal cancer operation with sharp dissection under direct vision, 
preserving the mesorectum within an intact endovisceral (mesorectal) fascia. The TME
procedure includes resection of the mesorectum together with the rectal tube and in case of 
anterior resection and Hartmann’s procedure dividing these structures distal to the tumour >5@.
Transanal endoscopic microsurgery (TEM)
A transanal technique for local excision of rectal tumours, using an operative rectoscope with 
optic magnification and endoscopic surgical instruments.
Anterior resection (AR)
A rectal resection and a colorectal or a coloanal anastomosis.
Abdominoperineal resection (APR)
Removal of the rectum and anus and construction of a terminal colostomy.
Hartmann’s procedure
A rectal resection with closure of the distal rectal tube and construction of a terminal
colostomy.
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Curative intent
A procedure with curative intent includes a local excision or rectal resection with the aim of 
cure, including patients with microscopic tumour involvement of any resection margin and/or 
patients having an intraoperative perforation of the tumour or bowel wall. 
Curative resection
A local rectal cancer excision or a major rectal cancer resection with the aim of cure, 
including patients with R0 and R1 stage.
Univariate analysis
Simple data descriptions including frequency and two-way contingency tables and risk 
analyses and survival analyses for one variable at a time.
Multivariate analysis
A statistical analysis describing interrelations among variables under study, and taking them
into account simultaneously.
Local recurrence (LR)
LR is defined as recurrent disease in the pelvis, including recurrence at the site of the bowel 
anastomosis or in the perineal wound >6@. LR rates are given as the sum of LR occurring in 
isolation and concomitant with distant metastases.
Relative survival
Relative survival is defined as the ratio of the observed survival in the study group to the 
survival of the general population from which they arise, matched for sex, age and period. 
Disease-free survival
Disease-free survival is the rate of survivors without verified LR or distant metastasis.
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American Society of Anaesthesiologists (ASA) classification >7,8@
ASA class I                the patient is healthy with no systemic disease, and the pathologic
                                   process for which operation is to be performed is localized 
ASA class II               there is a mild to moderate systemic disturbance caused either by the
 condition to be treated surgically or by pathophysiologic processes 
ASA class III              the patient either has multiple-system disease or well-controlled major
                                    systemic disease 
ASA class IV the patient has a severe systemic disorder that is already life
     threatening and may not be correctable by operation
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INTRODUCTION
Rectal cancer treatment in the 1970’s and 1980’s was characterized by high rates of local 
recurrence (LR) and poor overall survival >9-11@. The introduction of total mesorectal
excision (TME) reduced the rate of LR and improved the survival rates >4, 12, 13@. The results 
achieved in single centre series with rectal resection and TME technique were superior to 
those after conventional surgery, even when conventional surgery was combined with 
preoperative radiation or postoperative (chemo) radiation >10, 14-16@.
In  1993 a National Rectal Cancer Registry was established in Norway and in 1994 the 
Norwegian Rectal Cancer Group was founded. Through educational programmes for surgeons 
and pathologists TME was implemented as the standard rectal resection technique on a 
national level. Surveillance of and feedback to the hospitals have improved the results 
regarding LR and overall survival >17, 18@. There has been a continuous evaluation of the 
results, and national treatment guidelines based on preoperative tumour staging, intraoperative 
tumour perforation and postoperative evaluation of the circumferential resection margin
(CRM) have evolved >19-21@. Increasing hospital caseloads have proved to influence the rates 
of LR and overall survival, and as a consequence, the number of treating hospitals has been 
reduced >22@. In addition, there has been an enhanced focus on the diagnostic radiological 
modality techniques. Through preoperative staging with evaluation of surgical and 
pathological prognostic factors, differentiated rectal cancer treatment has developed >23-26@.
Preoperative radiation combined with TME technique has proved to reduce the risk of LR, but 
no benefit in survival has so far been observed in cases of resectable rectal cancer >27, 28@. At 
present the national guidelines recommend a selective use of (neo)-adjuvant therapy. Rectal 
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resection with TME technique, without neo-adjuvant therapy, is standard treatment in primary
resectable tumours. During the study period, major surgery combined with neo-adjuvant 
chemoradiation was used for patients with T4 tumours. Adjuvant chemoradiation was used for 
patients with histopathological verified CRM less than 1 mm or after intraoperative
perforation of the tumour >29@. Apart from this, neither radiotherapy nor chemotherapy has 
been an integrated part of rectal cancer treatment in Norway.
Although the results regarding LR and survival have improved after the introduction of TME, 
the rates of mortality, morbidity, and the functional disturbances after major surgery are
substantial >30-32@. As a consequence, the interest in locoregional treatment of preoperative
verified early rectal cancer has increased. Transanal endoscopic microsurgery (TEM) has 
been introduced into clinical practice and the results achieved are comparable to those after 
major surgery >33, 34@. Conventional transanal excision has also been recommended as 
definitive treatment, although there are considerable variation in the rates of LR and overall 
survival in different series >35, 36@.
The prognosis of younger rectal cancer patients is uncertain. A more advanced tumour stage 
at the time of diagnosis, more aggressive histopathologic characteristics, and inferior rate of 
survival has been described >37-39@. The results of major surgery in old rectal cancer patients
have been evaluated >40-42@. Although higher rates of postoperative mortality and a reduced 
overall survival compared to younger patients, properly selected elderly patients benefit from
major surgery. After the introduction of TME, no national population based series focusing on 
the influence of age on rectal cancer patients has been published. 
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 In Norway the majority of patients with early rectal cancer have been treated with major
rectal resection, and the national treatment guidelines have not differentiated on the age of the 
patient.
The work presented here is a part of a continuous process, initiated by the Norwegian Rectal 
Cancer Group, to improve the quality of rectal cancer treatment on a national level through 
differentiation of management strategies.
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AIMS OF THE STUDY 
      The specific aims of the present study were as follows: 
I. To evaluate the outcome of Transanal Endoscopic Microsurgery (TEM) when 
introduced as a new treatment strategy for rectal adenomas and for rectal cancer. 
      II.        To examine the long-term results of transanal excision compared with major
                  surgery in the treatment of T1 rectal cancer. 
      III.       To characterize clinicopathological issues according to different age groups,
             to evaluate the results of treatment and to assess whether a change in national
             treatment guidelines is indicated for young rectal cancer patients. 
IV. To evaluate rectal cancer treatment in the elderly patients and to assess the short
            and long-term results of major surgery after the implementation of the TME
            technique on a national level.
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METHODOLOGICAL CONSIDERATIONS
Study design 
The papers presented in this thesis are based on observational series of patients. Non- 
randomized clinical studies will always be at risk for potential confounding related to 
selection of subgroups of patients to different treatment modalities. In order to follow national 
treatment guidelines >29@, randomized design studies were considered not appropriate to 
evaluate treatment strategies for early rectal cancer, and neither concerning the influence of 
age on prognosis for rectal cancer. 
Papers II-IV are based on a nation-wide registration of relevant clinical information of all 
incident cases of rectal cancer in the period between 1993 and 2001. Data quality is believed 
to be high, both in terms of reliability and completeness of ascertainment, and the population-
based design in these studies reduces the risk of the potential biases inherent in single 
institution-based studies. Multivariate analyses have been performed to adjust for potential
confounding. Nevertheless, unmeasured confounders could still influence the results.
Paper I – a retrospective single centre series 
Paper I in this thesis is based on a cohort of seventy-nine patients treated by TEM for rectal 
adenoma or rectal cancer at the Department of Surgery, St. Olavs Hospital, University of 
Trondheim, between January 1994 and November 2001. St. Olavs Hospital is the largest 
hospital in the county of Sør-Trøndelag and a referral hospital for the counties of Nord-
Trøndelag and Møre & Romsdal (Health Region Mid-Norway), including approximately
650000 inhabitants. St. Olavs Hospital was the first hospital in Norway to introduce the TEM 
technique, and still is the only hospital in Health Region Mid-Norway performing this. The 
indication for TEM in this series was restricted to sessile rectal adenomas, and patients with 
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preoperative verified malignant tumours underwent TEM only as they were considered not fit 
for major surgery because of coexisting disease. The small number of patients reflects the 
selection of patients considered suitable for this procedure. Although being a referral hospital, 
the number of patients referred for TEM from other hospitals has been minute. Traditionally 
distal sessile rectal adenomas have been treated with conventional transanal excision, and 
sessile adenomas in the middle or upper part of the rectum and early rectal cancer by rectal 
resection. Due to these alternative treatment options, and possibly insufficient information
about this new technique, only a few patients were referred from other hospitals.
Although this is a non-randomized retrospective single-centre series, all the patients treated by 
TEM after its introduction until end of the study period were included. This consecutive series 
describes the feasibility and the results achieved when TEM was introduced as a new
technique in our department.
Papers II – IV – prospective national population based series 
Based on an initiative of the Norwegian colorectal community the Norwegian Rectal Cancer 
Group was initiated in 1994. In collaboration with The Cancer Registry of Norway a National 
Rectal Cancer Registry was established. The Norwegian Rectal Cancer Group, consisting of 
dedicated surgeons, oncologists, pathologists and epidemiologists, is running the Norwegian 
Rectal Cancer Project. Papers II – IV in this thesis are all parts of this project. 
The National Rectal Cancer Registry is population based, and since November 1993 all new 
cases of rectal cancer have been prospectively registered in a national database. The 
completeness of this registry is assured through a national obligatory reporting system for 
malignant diseases to The Cancer Registry of Norway, both for clinicians and pathologists. 
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Information on patient and treatment characteristics is achieved from the clinicians through 
their reports to The Cancer Registry of Norway and from a project specific form reported by 
the surgical departments. Information on tumour characteristics, TNM and R-stage is 
retrieved from the histopathology reports achieved from the pathologists. 
The national follow-up regimen is according to the guidelines of The Norwegian
Gastrointestinal Cancer Group >29@. Follow-up time is calculated as patient-months at risk. 
Date of operation is used as start of follow-up, and endpoints are LR, distant metastases or 
death regardless of cause.
Follow-up information regarding the use of adjuvant therapy, LR and distant metastasis is 
retrieved from the project specific forms, the pathology departments’ obligatory reports to the 
Norwegian Cancer Registry and from regular reminders to the surgeons at the treating 
hospital. The rate of LR is given as the sum of patients with isolated LR and of patients with 
both LR and distant metastasis. The rate of metastasis includes distant metastasis with or
without LR. Local recurrences and distant metastases develop over time, and cumulative rates 
are given.
Survival rates denote overall (crude), disease-free and relative survival. The Norwegian Cause 
of Death Registry provides information on time of death. Because of the low rate of autopsies 
in this national material, leading to possible bias, disease-specific survival is not reported. 
All the information retrieved from these various sources regarding patients with rectal cancer 
is crosschecked by trained staff members and stored in the database at The National Rectal 
Cancer Registry. The quality of the data is further secured through a continuous evaluation 
and publication of the results. As a feedback the surgical departments regularly receive their 
own results together with the national averages for comparison. In order to assure cooperation 
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between The National Rectal Cancer Registry and the treating hospitals, each surgical
department is free to use their own results for scientific purpose. National results are 
presented at postgraduate courses, focusing on the latest knowledge that can be drawn form
the database. Thus, important results of the project are transferred to the surgical community, 
thus establishing the bases for sharing new treatment strategies.
18
Statistics
The results regarding categorical variables in Paper I were presented as absolute numbers and 
frequencies while the sample median and the range were used to describe continuous 
variables.
In Paper II-IV patient, tumour and treatment characteristics of the different groups were 
described by frequency tables and compared using Oneway Anova, Mann-Whitney, Pearson 
Chi-Square or Fisher Exact tests depending on the type of variable and the number of events 
compared. Missing data were included as “not given”. 
LR, metastasis, overall and disease-free survival were estimated by univariate Kaplan-Meier
analyses and compared by log rank tests.
In Paper IV, when comparing survival among different age groups of patients with apparent 
differences in life expectancy due to chronological age, estimates of relative survival were 
made using the Estève method >43@.
Potential prognostic factors were evaluated by multivariate analyses with Cox proportional
hazards regression models for LR, metastasis and overall survival. Sensitivity analyses were 
performed to evaluate missing data by both including and excluding missing data as a 
separate category. In the final model, statistic significant and/or clinical relevant variables
were included. 
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SUMMARY OF PAPERS 
Paper I evaluated the outcome following TEM in a consecutive cohort of the initial seventy-
nine patients treated at St.Olavs Hospital between January 1994 and November 2001.
The indications for TEM were rectal adenoma in 72 patients and rectal cancer in seven
patients. The median age was 74 years and 32 (41%) patients were classified as ASA 3 and 4. 
The mean follow up was 24 months (1-95). 
Seven patients had complications. Two (2,5 %) patients had peroperative perforation in the 
intra-abdominal part of the rectum treated by laparotomy. Five (6%) patients had 
postoperative cardiopulmonal or surgical complications.
Six  (8%) patients had gas or faecal incontinence more than one year after the procedure.
Eight (11%) patients with benign pre-operative histopathological examination had cancer, 
although at an early stage.
The overall LR rate was similar for adenomas and for carcinomas (13%). In the group of 
patients with free histological margin after TEM for adenoma there were two (3%) 
recurrences, while none of the patients with free margin after TEM for carcinoma had LR.
In conclusion, TEM is a safe technique well tolerated also by high-risk patients. It should be 
the preferred method in patients with benign tumours in the middle and upper part of the 
rectum and in selected cases of early rectal cancer. Benign preoperative histology does not 
preclude malignancy, and some patients may need further treatment for unexpected 
malignancy. To avoid remnant tumour tissue after TEM, frozen sections of the margins
should be examined during the procedure.
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Paper II examined the long-term results of transanal excision compared to major surgery for 
T1 rectal cancer. This national cohort included all 291 patients with a T1M0 tumour within 15 
cm from the anal verge treated by anterior resection (AR), abdominoperineal resection (APR), 
Hartmann’s procedure or transanal excision in the period November 1993 – December 1999. 
256 patients were treated by major surgery and 35 patients by transanal excision. None of the 
patients had neoadjuvant therapy. 
11 % of the patients treated with major surgery had glandular involvement. There were no 
significant differences according to tumour localization, size and differentiation between 
Stage I and Stage III tumours.
Macroscopic tumour remnants (R2) occurred in 17% (6/35) of the transanal excisions, while 
major surgery obtained 100% R0 resections. After curative resection the five-year rate of LR 
was 12% in the transanal excision group compared to 6% after major surgery (p = 0.010).
Patients treated with transanal excision were older than patients having major surgery (mean
age 77 vs. 68 years (p < 0.001), and the overall five-year survival was 70% in the transanal 
excision group compared to 80% in the major surgery group (p = 0.04). 
In this study the main problem of transanal excision for early rectal cancer, was the inability
to remove all the malignancy. Patients treated with transanal excision had significant higher 
rates of LR compared to patients undergoing major surgery.
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Paper III evaluated the results of treatment for young rectal cancer patients. This national 
cohort included all 2283 patients younger than 70 years with an adenocarcinoma within 16 cm
from the anal verge treated between November 1993 and December 1999. Patients under 40 
years (n = 45), 40-44 years (n = 87), 45-49 years (n = 153) and 50-69 years (n = 1998) were 
compared.
Patients under 40 years had significant higher frequencies of poorly differentiated tumours 
(27% vs. 12-16%, p = 0.014), N2-stage (37% vs. 13-18 %, p = 0.001) and distant metastases
at the time of diagnosis (38 % vs. 19-24%, p = 0.019) compared to older patients. 
Among patients treated for cure by AR or APR with TME technique, 56% of the patients 
under 40 years developed distant metastases compared to 20-26% of the older patients (p = 
0.003). Overall five-year survival was 54% for patients under 40 years compared to 71-88% 
for the older patients (p = 0.029). Age less than 40 years was a significant independent 
prognostic factor and increased the risk for metastasis and death.
In conclusion, patients under 40 years had a more advanced stage at the time of diagnosis and 
poor prognosis compared to older patients. Patients younger than 40 years treated for cure 
more often developed distant metastases and had inferior survival.
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Paper IV focused on rectal cancer treatment among patients over 85 years. 4875 patients 
older than 65 years, treated between November 1993 and December 2001 for a tumour within 
16 cm from the anal verge, were included in this national cohort. Patients aged 65-74 (n = 
2086), 75-79 (n = 1223), 80-84 (n = 949) and over 85 years (n = 617) were compared.
There were more palliative surgery, local procedures and less surgery for cure (47% vs. 77%, 
p < 0.001) for patients over 85 years compared to younger patients. Five-year relative survival 
was 36% for patients over 85 years compared to 49% for patients 80-84 years and 60% for 
patients 65-74 years.
Among patients treated for cure with major surgery and TME technique, the rate of anterior 
resection decreased by age (67% vs. 46%, p < 0.001). Postoperative mortality increased from
3% to 8% (p < 0.001). There were no significant differences in the rates of five-year LR, 
distant metastasis or relative survival.
In conclusion, major rectal cancer surgery can be performed in properly selected patients over 
85 years. Although a slight increase in postoperative mortality, these patients had similar rates 
of LR, distant metastasis and relative survival as younger patients. Rigid treatment guidelines 
based on high chronological age should be avoided. 
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GENERAL DISCUSSION
An early rectal carcinoma is defined as TNM stage T1NxMx >44@. T1 tumours less than 3 cm
with histological low-risk tumour characteristics are considered suitable for full-thickness
local excision by TEM or conventional transanal excision without (neo) adjuvant therapy
>34, 44, 45@.
The selection of patients with rectal tumours suitable for locoregional treatment is based on 
preoperative examinations including endoscopy with biopsies and radiological staging.
Paper I demonstrates the challenges of this selection as 11 % of the patients with preoperative 
presumed adenomas had invasive cancer, although at an early stage. Larger adenomas may
have small malignant foci and multiple preoperative biopsies are required. A transmural rather 
than a mucosal local excision is advisable when possible. 
Endorectal Ultrasonography (ERUS) and MRI has proved to be the most accurate modalities
in preoperative radiological staging of rectal cancer >23@. The accuracy in determining wall 
penetration (T-stage) has been reported equivalent, whereas MRI is superior in determining
nodal involvement (N-stage). Thus MRI is considered the single most accurate investigation 
to predict pathological stage in rectal cancer >24@.
In early rectal cancer ERUS has been the most commonly used staging modality. However, 
some recent studies state a lower accuracy in assessing T-stage than previously reported,
particularly for early cancers >25, 46, 47@. The assessment of intramucosal and intramural
tumours has also been described as difficult when using MRI >26@.
On a national basis radiological staging prior to locoregional treatment of early rectal cancer 
depends on the accessibility of radiological modalities and experience and skills of the
surgeons. A wide variation in the accuracy of preoperative staging is likely.
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While major surgery for T1 rectal cancer, as presented in Paper II, assures complete removal
of the tumour, the ability of locoregional treatment to achieve R0 status was significantly 
impaired. All eight T1 tumours treated by TEM in paper I were completely excised, and
80 percent (51/64) of the adenomas had a free margin in the line of resection. After transanal 
excision of T1 tumours in paper II, there was only 46 percent R0 stage after the procedure.
The curative intent in the treatment of fit patients with T1 rectal cancer is absolute, and a 
complete removal of the tumour is imperative. Transmural excision with an adequate margin
of clearance and intraoperative frozen section of the tumour margins are mandatory in order 
to verify radical excision. 
The major concern regarding locoregional treatment of early rectal cancer has been the
possibility of leaving metastatic lymph nodes after the procedure. The overall risk for Stage 
III disease in patients with T1 rectal tumours is about 10 % >44, 48@, similar to the findings in 
Paper II.
Several previous series have evaluated potential predictors in order to differentiate between 
Stage I and Stage III rectal cancer. Well-established high-risk tumour characteristics are poor 
differentiation of the tumour, lymphovascular infiltration and mucinous subtype >44, 48, 49@.
More recently the Sm-classification has been developed, and sessile T1 tumours with invasion 
to the lower one-third of the submucosa are considered as high-risk tumours >44, 50@.
The information regarding these risk factors is mainly obtained from the postoperative
histopathological examination of the resected T1 lesion. In Paper II neither tumour
differentiation nor other preoperative verified variables, such as tumour diameter and distance
from anal verge, were significant predictors in the differentiation between Stage I and Stage 
III rectal cancer.
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The standard histopathological description of a locally excised T1 lesion should include 
adequate information regarding these high-risk tumour characteristics, and a close 
collaboration between the pathologist and the surgeon is important.
Fit patients with inadequate resection margin or high-risk tumour characteristics after 
locoregional treatment of early rectal cancer should receive additional treatment in order to 
obtain satisfactory treatment results. The long-term results after major surgery for failed 
locoregional treatment are inconsistent, although immediate rather than salvage surgery at the 
time of verified LR ought to be preferred >35, 51-53@. Adjuvant (chemo) radiation has also 
been advocated in single series on T1 tumours with adverse factors >45, 54, 55@.
The rates of LR and survival after transanal excision of T1 rectal cancer presented in Paper II 
are inferior to those after major surgery. As for other series on locoregional treatment of early 
rectal cancer, these findings are based on analyses of non-randomized cohorts of patients. 
Although some series evaluating locoregional treatment of T1 rectal cancer present results 
comparable to those after major surgery, there is a significant variation in the rates of LR and 
survival. The results achieved depend upon the selection criteria, surgical approach, use of 
adjuvant therapy, and study design.
The complication rates and the functional results after locoregional treatment are superior to 
those after major surgery >34-36, 56@. In the presented series 41% of the patients selected for
TEM were high-risk patients classified as ASA 3 or 4, and the patients treated by transanal 
excision in Paper II were significant older than those undergoing major surgery.
The selection of patients has been based on preoperative clinical evaluation. Although 
increased comorbodity among the locoregional treated patients must be assumed, the rates of 
complications and postoperative mortality were low. 
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Accurate preoperative staging, radical excision through adequate surgical technique and exact 
histopathological evaluation of the resected specimen are of paramount importance in order to 
achieve acceptable results after locoregional treatment of early rectal cancer. Locoregional
treatment without adjuvant therapy may be a safe alternative to major surgery in cases with 
completely excised T1 low-risk tumours.
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Paper III confirmed the finding of previous series considering young rectal cancer patients as 
a high-risk group with inferior prognosis >39, 57, 58@. However, previous studies frequently 
include both colon and rectal cancer patients, and none of the former studies have reflected 
the outcome after standardized rectal cancer surgery with TME technique.
The upper age limit of young patients in this perspective has been vague, but most series have 
classified patients under 40 years as young. In order to define a potential high-risk group 
among younger rectal cancer patients, this national cohort focused on the entire range of 
under average aged patients.
Rectal cancer patients under 40 years have higher frequencies of advanced disease at the time
of diagnosis. Information on time from symptoms to diagnosis was not stated in this cohort, 
and diagnostic delay may have influenced on the shift towards more advanced disease among
younger patients >38, 59@. The similarity in distribution of tumour size and T-stage between
the different age groups in the present series opposes this as the solitary explanation of this 
finding.
The distribution of patients with regional lymph node metastases (Dukes’ C) was similar, but 
the rate of patients with N2 stage, poorly differentiated tumours and distant metastases, were 
significantly higher among the youngest patients. Advanced tumour stage is correlated with 
inferior prognosis, and the overall five-year survival among all patients less than 40 years was 
only 38 percent, significantly inferior compared to the older. 
Predisposing factors such as IBD, FAP, HNPCC or a family history of colorectal cancer 
(CRC) have been described as a frequent finding among young CRC patients >38@. High-risk 
patients with IBD or FAP should preferably be treated with proctocolectomy before they 
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develop invasive carcinoma, and in this cohort only three patients had IBD or FAP at the time
of diagnosis. 
Information on HNPCC or family histories of CRC was not available. Carcinomas in HNPCC 
patients tend to be multiple and located in the proximal colon >58, 60@. In this series of rectal 
cancer patients the rate of synchronous cancer was similar in the different age groups. This 
contradicts that HNPCC or multifocal cancer, as seen in familiar cancer syndromes, was more
frequent among the youngest patients.
Due to the high rate of distant metastases at the time of diagnosis only 40 percent of the 
youngest patients in this series underwent a rectal resection with curative intent. Although 
there were no differences in the distribution of tumour stage or R-stage between the groups of 
patients treated for cure, the prognosis was still inferior among patients under 40 years. More 
than half of the youngest patients developed distant metastasis, and the five-year overall 
survival was significant inferior. 
Biologically more aggressive cancer and reduced regulation of tumour growth might account 
for the advanced stage at the time of diagnosis and the inferior prognosis among young rectal 
cancer patients >61, 62@. The indication for (neo) adjuvant therapy as a part of the standard 
treatment in this subgroup of patients has to be evaluated.
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During the last decades both the incidence of rectal cancer and the life expectancy have been 
increasing in Norway. In 1997-2001 the maximum age-specific incidence of rectal cancer in 
Norway was observed among patients aged 75-79 years in both genders >63@, and at the time
of diagnosis more than 40 percent of rectal cancer patients were older than 75 years. As a 
consequence, the number of fragile rectal cancer patients with additional systemic disease has 
and probably will continue to increase. Although the national results of rectal cancer 
treatment have improved after standardisation of surgical treatment with TME technique, a 
more selective and differentiated treatment strategy may be required among older patients 
with comorbidity. In order to guide clinicians concerning strategy, Paper IV focused on the 
characteristics and results of treatment among elderly rectal cancer patients.
The rate of surgically treated patients decreased by age. Coexisting medical disorders are
known to increase with age and influence on this finding. Diagnostic delay among the elderly, 
leading to a more advanced tumour stage at the time of diagnosis and inferior rates of 
resection should also be considered >64, 65@. In this series the staging of patients not 
undergoing surgery was inaccurate, and among patients undergoing surgery the rate of
inaccurate staging increased by age. Age related differences in stage at the time of diagnosis 
are possible.
Although the distribution of Dukes’ stage was similar in the age groups of surgical treated 
patients, there were significant differences in type of surgical procedure. Locoregional and 
palliative surgery was more common among the older patients, and the rate of curative 
resections decreased by age. The age of the patients and the increased comorbidity have 
influenced on the surgeons selection of operative procedure, and less extensive surgery was 
done in older patients. 
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When evaluating the entire cohort of patients older than 65 years, the relative survival
decreased by age. This indicates that the strength to recover from rectal cancer and its 
treatment decreased by age, although inferior effort and quality of treatment among the oldest 
patients might have influenced on this finding.
Adequate evaluation of the patient, awareness of the alternative treatment options and their 
expected results, is mandatory also among elderly rectal cancer patients. The selection of 
treatment should be based on accurate preoperative tumour staging, geriatric and 
anaesthesiologic considerations and the patients informed choice.
The rate of patients undergoing curative major surgery with TME technique decreased by age, 
but still this treatment was achieved in one-third of the patients aged over 85 years. Although 
high age has showed no negative effect on the functional results and rate of anastomotic 
leakage in recent series >64, 66-68@, the rate of restorative resections decreased by age, and 
more than half of the oldest patients had a colostomy. The oldest patients may have particular 
difficulties in stoma care, and a restorative resection should be considered when the patient is 
fit for major surgery. 
Despite higher postoperative mortality among patients aged over 80 years, the results 
regarding LR, metastasis and relative survival were similar among the different age groups of 
patients treated with curative major surgery. The higher rate of postoperative mortality among
the oldest is correlated to the selection of patients, and other series on rectal cancer treatment
of the elderly contradict this finding >40-42@. Irrespective of age, properly selected patients 
benefit from major rectal resection with TME technique. 
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CONCLUSIONS
The present studies illustrate the pros and cons associated with locoregional treatment of 
rectal adenomas and early rectal cancer:
- Preoperatively benign histology and adequate radiological staging do not preclude 
malignancy.
- The prediction of glandular metastasis, before or after local excision, is difficult, 
however essential, as 11% of the patients with T1M0 tumours have Stage III disease.
- The main problem of transanal excision of early rectal cancer is the inability to 
achieve R0 status, and after curative excision the rate of local recurrence is 
significantly higher than after major surgery. 
- To avoid remnant tumour tissue after locoregional treatment, frozen sections of the 
margins should be examined during the procedure. 
- TEM is a safe technique, also in high-risk patients, and should be the treatment of 
choice in patients with benign tumours in the middle and upper part of the rectum, and 
in selected cases of early rectal cancer.
Furthermore, the studies illustrate the influence of age on the prognosis in rectal cancer 
patients:
- Patients under 40 years have a more advanced stage at the time of diagnosis and poor 
prognosis compared to older patients. Patients under 40 years treated for cure with 
TME technique more often develop distant metastases and have inferior survival. 
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- Major rectal cancer surgery with TME technique can be performed in properly 
selected patients over 85 years. Although a slight increase in postoperative mortality,
these patients have similar rates of local recurrence, distant metastasis and relative 
survival as younger patients.
33
PERSPECTIVES
The enhanced national focus on rectal cancer and the introduction of the TME technique has 
improved the prognosis for rectal cancer patients. Through a continuous evaluation of the 
treatment results with focus on distinctive subgroups of patients, further improvement can be 
obtained.
To further assess locoregional treatment as an optional treatment of early rectal cancer large 
series of patients are required. The number of Norwegian hospitals performing TEM has 
increased, and a prospective national study, evaluating the results achieved by TEM, would be 
of importance concerning future national treatment strategies for early rectal cancer. 
In locoregional treatment of T1 rectal cancer the difficulties in predicting potential glandular
metastasis is of major concern. The large number of T1 tumours treated by major surgery with 
TME technique without chemo-radiation in the presented material is unique. Reassessment of 
the histopathological preparations, with evaluation of established and alternative predictive 
factors for Stage III disease among patients with T1 tumours, would be of importance.
The significant inferior prognosis among rectal cancer patients under 40 years requires further 
evaluation. Potential genetic factors related to reduced cell repair or tumour control and the 
indication for adjuvant therapy must be assessed. 
An enhanced focus on treatment of rectal cancer patients high at age and/or with severe 
comorbidity is justified. Alternative treatment regimens, including neo-adjuvant 
chemoradiation and locoregional treatment, should be evaluated.
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2ABSTRACT
Purpose The purpose of this national study was to evaluate the results of treatment for young
rectal cancer patients. 
Methods This prospective study from the Norwegian Rectal Cancer Project includes all 2283
patients younger than 70 years with adenocarcinoma of the rectum from November 1993 to
December 1999. Patients under 40 years (n = 45), 40-44 years (n = 87), 45-49 years (n = 153)
and 50-69 years (n = 1998) were compared for patient and tumor characteristics and five-year
overall survival. Patients treated for cure (n = 1354) were evaluated for local recurrence,
distant metastasis, and disease-free survival. 
Results Patients under 40 years had significant higher frequencies of poorly differentiated
tumors (27 percent vs. 12-16 percent, p = 0.014), N2-stage (37 percent vs. 13-18 percent, p =
0.001) and distant metastases (38 percent vs. 19-24 percent, p = 0.019) compared to older
patients. Among those treated for cure, 56 percent of the patients under 40 years developed
distant metastases compared to 20-26 percent of the older patients (p = 0.003). Overall five-
year survival was 54 percent for patients under 40 years compared to 71-88 percent for the
older patients (p = 0.029). Age less than 40 years was a significant independent prognostic
factor and increased the risk for metastasis and death. 
Conclusions Patients under 40 years had a more advanced stage at the time of diagnosis and
poor prognosis compared to older patients. Young patients treated for cure more often
developed distant metastases and had inferior survival. 
(Keywords: Rectal cancer, young patients, distant metastasis, overall survival)
3INTRODUCTION
Over the last decades the incidence of colorectal cancer (CRC) has increased, and at present it
is the second most frequent cancer in Norway.1 One-third of the CRC patients have rectal
cancer, with a world standardized age-adjusted incidence rate in 1997-2001 of 16 per 100 000
for males and 10 per 100 000 for females. The mean age of rectal cancer patients is 70 years.
The age-specific incidence of rectal cancer increases sharply after the age of 50 years, and in
Norway 5 percent of the patients are 50 years or younger. 
After the introduction of total mesorectal excision (TME) the results of rectal cancer treatment
have improved radically.2,3 In 1993 a National Rectal Cancer Registry was established in
Norway. Treatment guidelines based on tumor stage and surveillance of and feedback to the
hospitals have resulted in improved results according to local recurrence and overall survival.4
Neoadjuvant radiotherapy is standard treatment for patients with T4 tumors, and adjuvant
radiotherapy is used for patients with involvement of the circumferential resection margin
(CRM) or after intraoperative perforation of the tumor. Apart from this, neither radiotherapy
nor chemotherapy has so far been recommended as an integrated part of rectal cancer
treatment in Norway.  The national treatment guidelines have not differentiated on the age of
the patient.
The prognosis of younger patients with colorectal cancer is uncertain. Although the upper
agelimit of these patients remains undefined, most studies have classified patients under 40
years as young. Some studies have revealed a more advanced tumor stage at the time of
diagnosis,5-8 more aggressive histopathologic characteristics,9-16 and inferior rate of survival17-
21 in younger patients when compared to older ones. Other studies contradict these findings.22-
35 Most of these studies are single institution series, and to our knowledge, no national
4population based study, focusing on rectal cancer in the young after the introduction of the
TME technique, has been published.
The aims of this study were 1) to characterize the clinicopathologic issues according to
different age groups among younger rectal cancer patients, 2) to evaluate the results of
treatment, and 3) to assess whether a change in treatment guidelines is indicated 
for young rectal cancer patients. 
5METHODS
This study was a part of the Norwegian Rectal Cancer Project initiated in 1993. Since then all
new cases of rectal cancer have been prospectively registrated in a national database
according to patient, tumor and treatment characteristics. Detailed descriptions of the project
have been published by Wibe et al.4
Patient characteristics
In the period November 1993 – December 1999 a total of 5297 patients, with a mean age of
70 years, were treated for invasive rectal adenocarcinoma. Patients under 70 years of age were
selected, resulting in a study population of 2283 patients (43 percent) (Table 1). For further
analysis these patients were divided into four subgroups according to age (< 40, 40-44, 45-49
and 50-69 years). One thousand three hundred and fifty four patients with a rectal
adenocarcinoma within 16 cm from the anal verge, treated for cure by anterior resection (AR)
or abdominoperineal resection (APR) with total mesorectal excision (TME), were included in
the final analyses (Table 2). Rectal cancer surgery was performed at 47 hospitals.
Definitions
Patient and treatment characteristics were collected from the project specific forms. 
Information on tumor differentiation, TNM 36 and R-stage were retrieved from the 
histopathology reports. The R0-stage (residual tumor staging) denotes the group of patients
with a resection margin >1 mm, the R1-stage includes specimens with a margin 0-1 mm, the
RX-stage includes specimens where the circumferential resection margin was not specified
and R2-stage patients had macroscopic tumor remnants as denoted by the surgeon.
A resection with a curative intent includes all resections where the surgeon had the aim 
of cure, thus including patients with microscopic tumor involvement of the resection margin
and patients with intraoperative perforation of the tumor.
6The tumor level is given as the distance from the lower tumor border to the anal verge. The 
tumor diameter denotes maximum tumor diameter after fixation of the excised specimen. 
The Norwegian Cause of Death Registry provided information on time of death.
Postoperative mortality denotes mortality rates within 30 days of the procedure.
Synchronous cancer denotes concomitant active malignant disease at the time of the operative
treatment for rectal cancer.
Local recurrence was defined as clinically or histopatologically verified recurrent disease in
the pelvis, including the site of the bowel anastomosis and of the perineal wound, and was
retrieved from the project specific forms or the pathology departments obligatory reports to
the Norwegian Cancer Registry. The rate of local recurrence is given as the sum of the
patients with isolated local recurrence and the patients with both local recurrence and distant
metastasis. Metastases denote recurrent disease outside the pelvis. The rate of metastasis
includes distant metastasis with or without local recurrence. Survival rates denote overall
(crude) and disease-free survival. 
The follow-up regimen was according to the guidelines of The Norwegian Gastrointestinal
Cancer Group.37 Follow-up time was calculated as patient-months at risk. Date of operation
was used as start of follow-up, and endpoints were local recurrence, distant metastases or
death regardless of cause. The range of follow-up was 24-97 months. None of the patients
were lost to follow-up. End of follow-up was 31 December 2001.
Preoperative radiotherapy denotes a regimen of 2 Gy x 25 and postoperative radiotherapy
denotes 2 Gy x 25 and concomitant bolus of 5-fluorouracil. 
7Statistics
Patient, tumor and treatment characteristics of the different age groups were described by
frequency tables and compared using Fisher Exact or Oneway Anova tests (Table 1 and 2).
Missing data were included as “not given”.
Local recurrence, metastasis, overall and disease-free survival were estimated by univariate
Kaplan-Meier analyses and compared by log rank tests (Table 3 and 4).
Potential prognostic factors were evaluated by multivariate analyses with Cox proportional
hazards regression models for local recurrence, metastasis and overall survival (Table 5).
Sensitivity analyses were performed to evaluate missing data by both including and excluding
missing data as a separate category. In the final model statistic significant and/or clinical
relevant variables were included.
 Analyses were performed using SPSS® version 12.0 (SPSS Inc., Chicago, IL).
8RESULTS
All patients
Of the 2283 patients under 70 years diagnosed with rectal cancer, 45 patients were younger
than 40 years, 87 patients 40-44 years, 153 patients 45-49 years and 1998 patients 50-69 years
(Table 1). 
Three patients had predisposing conditions. Two patients had familiar adenomatous polyposis
and one had ulcerative colitis, these patients were treated with proctocolectomy. The
distribution of synchronous cancer was not significant different between the age groups (data
not given). The male/female ratio was lower in the two youngest age groups.
Patients under 40 years of age had a significant higher frequency of poorly differentiated
tumors, N2-stage and Dukes’ stage D compared to the older patients. 
The overall five-year survival was 38 percent in the group of patients younger than 40 years
of age, 70 percent for patients between 40 and 44 years, 62 percent for patients between 45
and 49 years and 56 percent for the group of patients between 50 and 69 years (p = 0.004)
(Table 3, Fig 1). The median survival for patients younger than 40 years was 40 months.
Patients treated for cure
Among the 1354 patients treated for cure, 18 patients were younger than 40 years, 54 patients
40-44 years, 92 patients 45-49 years and 1190 patients 50-69 years (Table 2). 
The male/female ratio was lower in the two youngest age groups. The frequency of poorly
differentiated tumors was higher for patients under 40 years, 22 percent vs. 7-19 percent for
older patients. Apart from this, there were similar tumor characteristics in the four age groups.
9There were no differences in the rate of intraoperative perforation or patients with R1 status;
however, postoperative radiotherapy was more often used in the youngest patients.
The five-year rate of local recurrence was 20 percent for patients under 40 years compared to
8-18 percent for older patients (Table 4).
Distant metastases occurred in 56 percent of the patients under 40 years, 22 percent for
patients 40-44 years, 20 percent for patients 45-49 years and 26 percent in the group of
patients between 50 and 69 years (Table 4, Fig 2). 
Overall five-year survival was 54 percent, 88 percent, 76 percent and 71 percent (Table 4, Fig
3), and disease-free survival was 44 percent, 74 percent, 70 percent and 61 percent, in the
same four groups respectively.
The risk of local recurrence was increased in males compared to females by a factor of 1.4
(Table 5). Age and tumor differentiation did not influence the rate of local recurrence. Young
age had a significant influence on the risk of developing distant metastasis. Being less than 40
years of age increased the risk of distant metastasis by a factor of 5.1 compared to patients
between 40 and 44 years. Higher age did not influence the rate of distant metastasis, and
neither did tumor differentiation.
Mortality was 50 percent higher in males than in females. The highest mortality was found in
the patients less than 40 years of age, being increased by a factor of 6.2 compared to the
patients aged 40-44 years. Tumor differentiation influenced on overall survival, and patients
with poorly differentiated tumors had an increased risk of death by a factor of 1.6 compared to
patients with well or medium differentiated tumors. 
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DISCUSSION
This study on rectal cancer describes patients less than 40 years of age as a high-risk group
with inferior prognosis. Several previous studies on colorectal cancer have demonstrated poor
prognosis in the young patients,17-21 although few studies report the influence of age on
clinicopathologic features and prognosis among the entire range of under average aged rectal
cancer patients. 
The majority of the studies on this topic are retrospective single institution series. Population
based studies include both colon and rectum cancer patients treated during longer time periods
between 1943 and 1999.6,14,24,26,27,31,33,34 The treatment protocols may have changed during
and after these periods. None of the former studies reflect the outcome of current surgical
practice for rectal cancer treatment using TME. The present study was based on a prospective
national cohort following standardized TME for rectal cancer. 
Over the last decades, the median age of colorectal cancer patients in Norway has increased.38
The median age in this national cohort from 1993 to 1999 was 72 years. This may in part
explain the low frequency of rectal cancer patients less than forty years of age, 0.9 percent in
this series. Older colorectal population based series, and series with longer time-span, report a
higher frequency, ranging from 1.1 to 5.4 percent.6,26,27,31,33,34,35  Compared to colon tumors
the proportion of rectal tumors is lower in patients below the age of 40 years.26 Higher
frequencies in single institution series may be the result of referral-center experience or
because of different age ranges in series from developing countries.10-12,16
In the literature an average of 16 percent of the young colorectal carcinoma patients have
predisposing factors (inflammatory bowel disease, familial adenomatous polyposis (FAP) or
hereditary non-polyposis colorectal cancer syndrome (HNPCC), and 23 percent have a family
11
history of colorectal cancer.12 Some series find a similar rate of family history in young and
old colorectal cancer patients.7,9,18  Different molecular biological features of the tumor, with
higher frequency of acquired 9 or inherited microsatellite instability as in HNPCC 23 in the
young have been described. 
In this cohort only three patients had predisposing conditions (FAP or ulcerative colitis) at the
time of diagnosis, indicating that these high-risk groups achieve adequate treatment
(proctocolectomy) before they develop invasive rectal carcinoma. Information on HNPCC or
family histories of colorectal carcinoma was not available. HNPCC carcinomas tend to be
multiple and have a proximal location in the colon,9,14,21,31 but there were no differences in the
distribution of synchronous cancer between the age groups in this series. Multifocal cancer, as
seen in familiar cancer syndromes, was not more frequent among the young rectal cancer
patients. 
Higher frequencies of tumors in advanced stage at the time of diagnosis,5-9,12-14,16-18,20,21,30,35
and of poor differentiation,6,7,9-22,24,35 have been pointed out in several studies on young
colorectal patients. This is consistent with the present series where a significant higher
proportion of patients with multiple regional glandular metastases (N2), distant metastases
(Dukes` D) and poorly differentiated tumors were found among patients under 40 years. In
this study the high proportion of young patients presenting with an advanced stage of disease
correlates with a higher incidence of histologic aggressive tumors. Other histopathologic
indicators of aggressive tumorbiology include mucinous component, signet-ring cell
carcinoma, perineural, vascular and lymphatic invasion.11-15,28,29,32 These variables have not
been routinely reported in this national study. Neither have the molecular biologic
characteristics known to regulate tumor growth.23
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Diagnostic delay has been argued to be another factor causing more advanced disease in
young colorectal patients.8,11,17,25,27,28 Time from symptoms to diagnosis was not stated in this
cohort, but there were no significant differences between the age groups according to T-stage
or tumor diameter at the time of diagnosis. 
Young patients with colorectal cancer are reported to have a poor survival compared to older
patients.12,16-18,20,21 The univariate analysis on overall survival in this series, including all
patients diagnosed with rectal cancer, shows a significant lower survival rate in patients under
40 years. It is well known that advanced tumor stage is correlated with inferior survival.8,11,16-
18,20,29,32 Biologically more aggressive cancer rather than diagnostic delay appears to account
for the advanced stage at the time of diagnosis leading to poor survival rates in young rectal
cancer patients, and this phenomenon may also explain inferior prognosis for young patients
treated for cure.
Previous reports from this project have demonstrated the effect of hospital caseload and
inadvertent perforation of the tumor on outcome of rectal cancer treatment.39,40 The present
results showing inferior prognosis for patients less than 40 years were not related to low
hospital caseload or high rates of peroperative perforation. These risk factors had similar
distribution in the different age groups (data not given).
The use of postoperative radiotherapy was significant higher in the youngest age group. This
may be explained by the fact that the treating hospitals have omitted the current national
treatment guidelines in an effort to give the youngest patients what they presumed was the
best possible treatment. Due to the small number of younger patients, the effect of adjuvant
radiotherapy was indistinct. There were no significant differences between the age groups
regarding local recurrence, and despite a more frequent use of postoperative radiotherapy, the
youngest patients still had the highest rate of local recurrence. 
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Some series on colorectal cancer comparing young and old patients demonstrate similar
overall survival rates.23,25,26,33 These series state no differences in stage and histopathologic
characteristics. Other studies state similar survival when comparing young and old patients
with similar tumor stage.8,9,11,13,15,24,28,35 In the present analyses on patients treated with
curative intent there were no significant differences according to T-stage, N-stage or Dukes’
stage between the age groups, but a significant higher incidence of poorly differentiated
tumors among the younger patients. 
Although the number of young patients is small, this national cohort suggests age as a
significant and independent prognostic factor according to metastasis and survival for rectal
cancer. Patients under 40 years had five times higher risk of metastasis and six times higher
risk of death compared to patients between 40 and 44 years. The youngest rectal cancer
patients seem to have additional negative prognostic factors, not related to histopathologic
findings or tumor stage. Genetic factors, related to reduced cell repair or tumor control, must
be considered.9,23 This theory supports the present findings of more N2 stage and Dukes’ D at
diagnosis as well as more distant metastases following curative treatment in patients younger
than 40 years.
14
CONCLUSION
This national cohort study of rectal cancer patients found that patients under 40 years had
poor prognosis compared to older patients. The younger patients not only had more advanced
stage at the time of diagnosis, but also patients treated for cure more often developed distant
metastases and had inferior survival. Young rectal cancer patients may have more aggressive
tumor biology and possibly reduced regulation of tumor growth. 
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Table 1  Patient and Tumor Characteristics of 2283 Patients under 70 Years of Age with Rectal Cancer
< 40 years 40 - 44 years 45 - 49 years 50 - 69 years
n    (%) n  (%) n   (%) n   (%) P*
45    (2) 87   (4) 153   (7) 1998   (88)
Age, mean(range) 34(16-39)   43(40-44)   48(45-49)   62(50-69)
Gender < 0.001**
  Female  26    (58) 54   (62) 67   (44) 788   (39)
  Male  19    (42) 33   (38) 86   (56) 1210   (61)
Lower border (cm), mean(range) 9.6(0-18) 8.6(1-18) 9.2(0-19) 9.4(0-20) 0.395  ***
Tumor diameter (cm), mean(range) 5.1(0-10) 4.5(1-10) 4.6(1-11) 4.5(0-20) 0.193  ***
Differentiation
  G1 (well)   4     (9)  4     (5)  11    (7) 147   (7) 0.782 **
  G2 (medium) 24    (53) 61   (70) 104   (70) 1430   (72) 0.056 **
  G3 (poor) 12    (27) 14   (16)  24   (16) 237   (12) 0.014 **
  Not given   5    (11)  8    (9)  14     (7) 184   (9)
T-stage
  T1      3      (7) 13   (15) 14    (9) 168     (8) 0.212 **
  T2 9    (20) 10   (12) 41   (27) 406   (20) 0.041 **
  T3 21    (47) 44   (51) 72   (47) 1082   (54) 0.256 **
  T4 12    (27) 17   (20) 22   (14) 312   (16) 0.167 **
  Not given 0    (0) 3   (3)   4     (3)  30     (2)
N-stage
  N0 16    (37) 45   (52) 81   (53) 1097   (55) 0.073 **
  N1 8    (19) 21   (24) 37   (24) 484   (24) 0.833 **
  N2 16    (37) 16   (18) 24   (16) 263   (13) 0.001 **
  Not given 5     (11) 5   (6) 11   (7) 154   (8)
Dukes' stage
  A 9     (20) 16   (18) 41   (27) 443   (22) 0.451 **
  B 7    (16) 24   (28) 36   (24) 588   (29) 0.092 **
  C 11    (24) 24   (28) 43   (28) 542   (27) 0.971 **
  D 17    (38) 21   (24) 28   (18) 385   (19) 0.019 **
  Not given 1     (2) 2   (2) 5   (3) 40   (2)
  Between the Age Groups*
  Fisher Exact **
  Oneway Anova***
Table 2  Characteristics of 1354 Patients under 70 Years of Age treated with Curative  AR or APR  and TME Technique 
< 40 years 40 - 44 years 45 - 49 years 50 - 69 years
         n    (%)      n     (%)       n     (%)       n     (%) P*
Total number treated 18    (1) 54   (4) 92   (7) 1190   (88)
Age, mean(range) 34(18-39) 43(40-44) 48(45-49) 62(50-69)
Gender < 0.001**
  Female 13   (72) 34   (63) 41   (45) 473   (40)
  Male 5   (28) 20   (37) 51   (55) 717   (60)
Lower border (cm), mean(range) 9.0(3-15) 8.7(1-16) 8.2(0-16) 8.8(0-16) 0.682***
Operative treatment 0.459**
  AR 15   (83) 37   (69) 63   (69) 875   (73)
  APR  3    (17) 17   (32) 29   (32) 315   (27)
Tumor diameter (cm), mean(range) 4.7(0-9) 4.4(1-10) 4.4(1-8) 4.4(0-12) 0.846***
Differentiation
  G1 (well)   1    (6) 4   (7) 10   (11) 96   (8) 0.783**
  G2 (medium) 12   (67) 39   (72) 70   (76) 903   (76) 0.702**
  G3 (poor)   4   (22) 10   (19) 6   (7) 118   (10) 0.039**
  Not given  1    (6) 1   (2) 6   (7) 73   (6)
T-stage
  T1 1   (6) 10   (19) 8   (9) 106   (9) 0.138**
  T2 6   (33) 9   (17) 33    (36) 306   (26) 0.055**
  T3 9   (50) 29   (54) 43   (47) 681   (57) 0.230**
  T4 2   (11) 6   (11) 8    (9) 97   (8) 0.689**
  Not given 0   (0) 0   (0) 0   (0) 0   (0)
N-stage
  N0 10   (56) 33   (61) 54   (59) 779   (66) 0.416**
  N1  4   (22) 13   (24) 28   (30) 280   (24) 0.510**
  N2  4   (22) 8   (15) 10   (11) 130   (11) 0.324**
  Not given 0   (0) 0     (0)  0    (0)    1     (0)
Dukes' stage
  A 5   (28) 14   (26) 30   (33) 343   (29) 0.844**
  B 5   (28) 19   (35) 24   (26) 436   (37) 0.202**
  C 8   (44) 21   (39) 38   (41) 410   (35) 0.404**
  Not given 0     (0) 0     (0)   0    (0)   1      (0)
R-stage 0.853**
  R0 17   (94) 49   (91) 87   (95) 1105   (93)
  R1  1     (6)  5     (9)  5     (5)    85     (7)
Preoperative radiotherapy 0.984**
  Yes   1     (6)   3     (6)   6     (7)     72    (6)
  No 17   (94) 51   (94) 86   (94) 1118   (94)
Postoperative radiotherapy 0.021**
  Yes   4   (22)   6   (11)    7    (8)     69     (9)
  No 14   (78) 48   (89) 85   (92) 1121   (94)
Postoperative mortality (30 days) 0.854**
  Yes 0     (0) 0     (0) 0     (0) 17    (1)
  No 18   (100) 54   (100) 92   (100) 1173   (99)
  Between the Age Groups *
  Fisher Exact **
  Oneway Anova***
  AR = anterior resection
Table 3    Five-year Overall Survival According to Age Group, 
2283 Patients under 70 years of Age with Rectal Cancer
Age Group No of Patients Overall Survival
n        %    95% CI*   p = 0.004**
    < 40 years 45       38    23 - 54
   40 - 44 years 87       70    60 - 80
   45 - 49 years 153       62    53 - 71
   50 - 70 years 1998       56    53 - 58
   Total 2283       56    54 - 59
   * Kaplan-Meier, ** log rank test
Table 4  Five-year Local Recurrence, Metastasis, Overall Survival and  According to Age Group, 1354 Patients
 under 70 years of Age treated with Curative AR or APR and TME technique for Rectal Cancer
   Age Group No of Patients   Local Recurrence      Metastasis   Overall Survival
n    %     95% CI*   p = 0.264** %    95% CI*   p = 0.003** %    95% CI*   p = 0.029**
    < 40 years 18   20     0 - 41       56     33 - 79             54     27 - 81       
   40 - 44 years 54     8     0 - 18       22     11 - 34       88     79 - 97
   45 - 49 years 92   18     9 - 26       20     11 - 28       76     66 - 86 
   50 - 70 years 1190   14   12 - 16       26     24 - 29       71     68 - 74
   Total 1354   14   12 -16       26     23 - 28       72     69 - 75
   * Kaplan-Meier, ** log rank test
  AR = anterior resection
Table 5 Factors influencing Local Recurrence, Overall Survival and Metastasis 
            after Curative APR/AR with TME Technique in 1354 Patients with Rectal Cancer
      Local Recurrence           Metastasis      Overall Survival
Variable  HR            95% CI            P* HR            95% CI              P* HR            95% CI             P*
Gender                                          0.043                                          0.030                                       < 0.001
  Female   1              Reference    1             Reference    1             Reference
  Male   1.4          1.0 - 2.0   1.3           1.0 - 1.7   1.5           1.2 - 1.9
Age group                                          0.181                                        < 0.001                                         0.012
  40 - 44    1             Reference    1             Reference    1             Reference
  < 40   5.7           1.0 - 34.3   5.1           2.1 - 12.0   6.2           2.0 - 19.7
  45 -49   4.8           1.1 - 21.1   1.1           0.5 - 2.3   2.5           0.9 - 6.9
  50 -69   3.7           0.9 - 14.8   1.2           0.7 - 2.2   3.3           1.4 - 8.0
T - Stage                                          0.003                                        < 0.001                                        < 0.001
  T1    1             Reference    1             Reference    1             Reference
  T2   1.5           0.6 - 4.0   1.0           0.5 - 2.2   0.9           0.5 - 1.7
  T3   2.6           1.0 - 6.4   3.1           1.5 - 6.3   2.1           1.1 - 3.8
  T4   4.0           1.5 - 10.7   5.2           2.4 - 11.1   5.0           2.6 - 9.4
N - stage                                         < 0.001                                        < 0.001                                        < 0.001
  N0    1             Reference    1             Reference    1             Reference
  N1   1.8           1.2 - 2.5   2.0           1.5 - 2.6   1.6           1.2 - 2.0
  N2   2.6           1.7 - 4.0   3.7           2.8 - 5.0   2.9           2.2 - 3.9
Differentiation                                          0.860                                          0.293                                          0.002
  Well/Medium    1             Reference    1             Reference    1             Reference
  Poor    1.0          0.6 - 1.7    1.2          0.9 - 1.6    1.6          1.2 - 2.1
AR = anterior resection; APR = abdominoperineal resection; TME = total mesorectal excisison; HR = hazard ratio; CI = confidence interval
* Cox regression
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Legends
Figure 1.      Overall survival by age group for all rectal cancer patients, p = 0.004
Figure 2.      Distant metastasis by age group in patients with curative resection, p = 0.003
Figure 3.      Overall survival by age group in patients with curative resection, p = 0.029
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2Abstract
Objective Life expectancy and incidence of rectal cancer have been increasing. The purpose
of this study was to evaluate rectal cancer treatment among very old patients.
Methods This prospective national cohort study includes all 4875 rectal cancer patients in
Norway over 65 years treated between November 1993 and December 2001. Patients aged
65-74, 75-79, 80-84 and over 85 years were compared for patient-, tumour- and treatment
characteristics and relative survival. 2840 patients treated for cure with major surgery and
TME technique were further evaluated for postoperative mortality, five-year local recurrence,
distant metastasis and disease-free survival.
Results There were more palliative surgery and local procedures and less surgery for cure
(47% vs. 77%, p < 0.001) for patients over 85 years compared to younger patients. Five-year
relative survival was 36% for patients over 85 years compared to 49% for patients 80-84 years
and 60% for patients 65-74 years. Among patients treated for cure with major surgery the rate
of anterior resection decreased by age (67% vs. 46%, p < 0.001). Postoperative mortality
increased from 3% to 8% (p < 0.001). There were no significant differences in the rates of
five-year local recurrence, distant metastasis or relative survival.
Conclusion Although a slight increase in postoperative mortality, major rectal cancer surgery
can be performed in very old patients. These patients had similar rates of local recurrence,
distant metastasis and relative survival as younger patients. 
Keywords Rectal cancer, elderly, major surgery, relative survival 
3Introduction
Rectal cancer is predominantly a disease of the elderly. At the time of diagnosis more than 
40% of rectal cancer patients in Norway were older than 75 years, and the maximum age-
specific incidence in 1997-2001 was observed among patients aged 75-79 years in both sexes
[1]. As the incidence of colorectal cancer has been increasing, and the population is getting
increasingly older [2], rectal cancer treatment in the elderly has to be evaluated in order to
elucidate the challenge of this problem.
Several previous series have evaluated the results of major surgery in old colorectal cancer
patients [3-11]. Surgical standards have been improved during the last decade, but
comorbidity has to be born in mind when deciding between major surgery and local resection
for fragile patients. Although higher rates of postoperative mortality and a reduced overall
survival compared to younger patients, properly selected elderly patients benefit from major
surgery. Most series include both colon and rectal cancer patients, and selected series on
major rectal cancer surgery in old patients are few, retrospective and based on single centre
experience [12-14]. After the introduction of total mesorectal excision (TME) no national
population based series with focus on elderly patients has been published. 
In 1993 a National Rectal Cancer Registry was established in Norway. Major surgery with
TME [15,16] was implemented as the standard treatment of rectal cancer. Treatment
guidelines based on tumour stage, surveillance of treatment and feedback of results to the
hospitals have improved the results according to local recurrence and overall survival [17,18].
The national treatment guidelines have not taken into account the age of the patient.
4The purpose of this study was to evaluate rectal cancer treatment in very old patients and to
assess the short and long-term results of major surgery after the implementation of the TME
technique on a national level. The study focuses on types of resection, rates of curative
treatment, postoperative mortality, and relative survival. In this setting, the group of patients
over 85 years were compared to patients 65-74 years, 75-79 years and 80-84 years.
5Materials and methods
This study was part of the Norwegian Rectal Cancer Project initiated in 1993. Since then all
new cases of rectal cancer have been prospectively registered in a national database according
to patient, tumour and treatment characteristics. Wibe et al have described the project in detail
[17].
Patient characteristics
In the period November 1993 – December 2001 a total of 7253 patients, with a mean age of
71 years, were diagnosed with invasive rectal adenocarcinoma. Patients over 65 years with a
tumour within 16 cm from anal verge were selected, giving rise to a study population of 4875
patients (67%). For further analyses these patients were divided into four subgroups according
to age (Table 1). 2840 patients treated for cure by anterior resection, abdominoperineal
resection or Hartmann’s procedure and TME technique were included in the final analyses
(Table 3). Rectal cancer surgery was performed in 50 hospitals.
Definitions
Patient and treatment characteristics were collected from project specific forms. Local
treatment procedures included transanal excision, transanal endoscopic microsurgery (TEM),
polypectomy and laser ablation. Palliative procedures included major surgery without tumour
removal. Information on tumour differentiation, TNM [19] and R-status were retrieved from
the histopathological reports. The R0-stage (residual tumour staging) denotes the group of
patients with a resection margin >1 mm, the R1-stage includes specimens with a margin 0-1
mm and R2-stage patients had macroscopic tumour remnants as denoted by the surgeon.
A resection with a curative intent includes all resections where the surgeon had the aim of
cure, thus including patients with R0- and R1-stage. 
6The tumour level is given as the distance from the lower tumour border to the anal verge. The 
tumour diameter denotes maximum tumour diameter after fixation of the excised specimen. 
The Norwegian Cause of Death Registry provided information on time of death.
Postoperative mortality denotes mortality rates within 30 days of the procedure.
Local recurrence was defined as clinically or histopatologically verified recurrent disease in
the pelvis, including the site of the bowel anastomosis and of the perineal wound, and was
retrieved from the project specific forms or the pathology departments` obligatory reports to
the Norwegian Cancer Registry. The rate of local recurrence is given as the sum of the
patients having isolated local recurrence and the patients with both local recurrence and
distant metastasis. Metastases denote recurrent disease outside the pelvis. The rate of
metastasis includes distant metastasis with or without local recurrence. Survival rates denote
overall (crude), disease-free survival and relative survival. Relative survival is the ratio of the
observed survival in the study group to the survival of the general population from which they
arise, matched for sex, age and period.
Preoperative and postoperative radiotherapy denotes 2 Gy x 25 and concomitant bolus of 5-
fluorouracil as a radio sensitizer. Adjuvant chemotherapy has not been a part of the standard
treatment regimen. Neoadjuvant radiotherapy was used for patients with T4 tumours, and
adjuvant radiotherapy for patients with involvement of the circumferential resection margin
(CRM) or after intraoperative perforation of the tumour. 
The follow-up regimen was according to the guidelines of The Norwegian Gastrointestinal
Cancer Group [20]. Follow-up time was calculated as patient-months at risk. Date of
operation was used as start of follow-up, and endpoints were local recurrence, distant
metastasis or death regardless of cause. The range of follow-up was 24-121 months. None of
the patients were lost to follow-up. End of follow-up was 31st December 2003.
7Statistics
Patient, tumour and treatment characteristics of the different age groups were described by
frequency tables and compared using Pearson Chi-Square, Fisher Exact or Oneway Anova
tests (Table 1 and 3). Missing data were included as “not given”.
Local recurrence, distant metastasis, overall, and disease-free survival were estimated by
univariate Kaplan-Meier analyses and compared by log rank tests (Tables 2 and 4).
Estimates of relative survival were made using the Esteve method. Analyses were performed
using STREL in the statistic package STATA.
Potential prognostic factors were evaluated by multivariable analyses with Cox proportional
hazards regression models for local recurrence, distant metastases and overall survival (Table
5). Sensitivity analyses were performed to evaluate missing data by both including and
excluding missing data as a separate category. In the final model statistically significant
and/or clinically relevant variables were included.
Except from estimates of relative survival, all other analyses were performed using SPSS®
version 13.0 (SPSS, Chicago, Illinois, USA).
8Results
All patients
The characteristics of the 4875 patients with invasive rectal cancer are described in Table 1.
The rates of patients undergoing surgery (96% - 78%, p < 0.001) and patients undergoing
curative resection (77% - 47%, p < 0.001) were decreasing with age. 
There were significant differences in type of surgical procedure between the age groups.
Palliative surgery, local procedures and Hartmann’s procedure were more common among
older patients, while anterior resection was less common for these patients, 29% for patients
over 85 years compared to 58% for patients 65 – 74 years. Among patients undergoing
surgery, there were no differences in Dukes’ stage at the time of operation, but after the
procedure, the rate of patients with R2-stage was significant higher among the oldest patients,
36% for patients over 85 years vs. 19% for patients 65 – 74 years (p < 0.001).
The overall five-year survival was 51% in the group of patients between 65 and 74 years of
age, 38% for patients between 75 and 79 years, 28% for patients between 80 and 84 years and
14% among patients over 85 years (p < 0.001) (Table 2). 
The five-year relative survival was 60%, 53%, 49% and 36% in the same four age groups
respectively (Table 2, Fig 1).
9Patients treated for cure
2840 (58%) patients were treated with curative major resection and TME technique (Table 3).
The rate of T1 tumours treated by major resection decreased with age, from 10% for patients
65 – 74 years compared to 3 % for patients  85 years (p = 0.002), reflecting the more
common use of local procedures in old, fragile patients. Similarly, both preoperative (8% vs.
2%, p < 0.001) and postoperative (6% vs. 1%, p = 0.001) radiotherapy were less used for
older patients.
There were different types of surgical procedures according to the age groups. Hartmann’s
procedure was more often preferred among the oldest patients, 21% for patients over 85 years,
compared to 5% for patients 65 – 74 years, and 54% of the patients over 85 years had a
permanent colostomy. In spite of a lower rate of restorative resections, the postoperative
mortality was 8% for the oldest patients compared to 3% for the youngest patients (p <
0.001).
There were no significant differences between the age groups regarding local recurrence or
distant metastases. The five-year rate of local recurrence ranged from 12% to 17%, and the
five-year rate of distant metastases ranged from 24% to 17% (Table 4).
Overall five-year survival and disease-free survival decreased significantly with age (Table
4). Relative five-year survival showed, however, an insignificant decreasing tendency with
increasing age, and was 77%, 70%, 72% and 65% in the four groups respectively (Table 4,
Fig 2). 
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T-stage and N-stage influenced the rate of local recurrence, distant metastases and overall
survival, with an increased risk in the more advanced stages (Table 5). Compared to the R0
stage, a resection margin between 0-1 mm (R1) increased the risk of developing local
recurrence by a factor of 1.7, distant metastases by a factor of 1.9 and death by a factor of 1.4.
Age influenced the risk of developing distant metastases, as patients aged over 85 years had a
decreased relative risk of 0.5 compared to patients 65-74 years of age.
Age and sex had a significant influence on overall survival. The mortality was 30% higher in
males than in females, and risk of death increased with increasing age. Compared to patients
65-74 years, the oldest patients had an increased risk of death by a factor of 2.8. Patients
treated with abdominoperineal resection or Hartmann’s procedure had an increased risk of
death by a factor of 1.3 and 1.5 respectively, compared to the patients treated with anterior
resection.
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Discussion
Major rectal cancer surgery with TME technique can be performed in selected elderly patients
with acceptable results according to short and long-term survival. Although a higher
postoperative mortality and a decreasing overall survival rate with increasing age, the relative
survival is similar for selected rectal cancer patients in all age groups. Previous single centre
studies on rectal cancer treatment in the elderly confirm this finding [12-14]. 
The proportion of colorectal cancer patients having surgical treatment is decreasing with age
[3,5,9,12]. In this series the rates of curative surgery were lower than in previously reported
series on rectal cancer and in series on colorectal cancer [3,5,8,9,11,14]. Higher resection
rates in single centre series might be a result of selection or specialised centre experience. The
resection rate in series including colon cancer may be higher due to the differences in
anatomic location and surgical strategies between colon and rectal cancer. 
Coexisting medical disorders, although not recorded in this series, increase with age and
influence on the selection of therapy. More advanced tumour stage at presentation, due to
diagnostic delay among the elderly, has also been considered, and could cause reduced
resection rates with increasing age [3,4,6,10]. The staging of patients not undergoing
operative treatment may be inaccurate, and as in other series, the frequency of inaccurate
staging among those operated increases with age [3]. Although there were no differences in
Dukes’ stage between the groups of operated patients, age related differences in stage at the
time of presentation is possible.
Despite similar Dukes’ stage at the time of operation, there were significant differences
between the age groups in type of surgical procedure, and the rate of palliative treatment was
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increasing with age. Local procedures can be an adequate treatment in cases of T1 rectal
cancer [21], and compared to major surgery the rate of postoperative morbidity and mortality
is low following local procedures. Therefore local excision should be the treatment of choice
in fragile patients. In this series the proportion of local treatment increased with age, but when
we excluded patients with distant metastasis at the time of operation, the proportion of T2 and
T3 tumours treated with local procedures, was significant higher among patients over 80 years
(data not given). This was possibly due to comorbididty. Local treatment of T2 tumours
without (neo)-adjuvant therapy, and of T3 tumours, should be considered as palliative
procedures. Sufficient preoperative staging of rectal cancer, also in the elderly, is imperative
to select the appropriate type of procedure and to predict the results of the chosen treatment.
The general status of the patient, strongly related to high age, has influenced on the surgeons
choice of operative procedure. Less extensive surgery was done in older patients, leading to
an inferior rate of curative resections, and may in part reduce relative survival among patients
over 80 years. 
In this series, elderly patients undergoing curative major surgery more often received a
permanent colostomy. Although there were no differences in tumour level between the age
groups, both the rate of patients undergoing abdominoperineal resection and Hartmann’s
procedure increased with age. In recent series evaluating the functional results [22,23] and the
rate of anastomotic leakage [3,24] after restorative resections, high age had no negative effect.
Older patients with colostomy may be unable to manage the stoma care themselves, and their
quality of life may be reduced. Primary anastomosis with a diverting stoma reduces the risk of
anastomotic leakage, [24] but it is a two-step procedure and could also increase the rate of
morbidity and mortality. The decreasing rate of restorative resections with age might be based
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on the discretion of the surgeons to avoid potential postoperative complications in fragile
patients. 
Regardless of different treatment regimens for rectal cancer, previous series have shown a
reduced use of chemo-radiation with increasing age [4,6,12,25,26]. The interface between
treatment effects, toxicity of (neo)-adjuvant therapy, and age in rectal cancer has not been
sufficiently evaluated, but an increased rate of mortality and toxicity in radiotherapy treatment
of older patients has been suggested [26,27]. Although no significant differences in T-stage or
R-stage between the groups of selected patients undergoing major surgery with curative intent
in this study, both the use of pre- and postoperative radiotherapy was significant lower among
the oldest patients. The suboptimal use of radiotherapy among the elderly, omitting the
national treatment guidelines, might be based on the clinician’s evaluation or the patient’s
choice. Due to the stringent use of radiotherapy in this series, leading to a small number of
patients at risk, further assessment of the consequence of this finding was unfeasible. 
Previous studies on colorectal cancer have shown significant higher postoperative mortality
rates in the elderly patients [3,5,6,9,11], while series on rectal cancer contradict this finding
[12,13,14].  Emergency surgery, ASA stage and age have been described as independent risk
factors influencing on postoperative mortality [5,9,11,13], but compared to colon cancer,
emergency presentation is less common in rectal cancer [14]. 
The univariate analyses on local recurrence and distant metastases in patients selected for
curative major surgery revealed no significant differences between the age groups. The
multivariate analyses confirmed that age had no significant influence on the rate of local
recurrence, while the rate of distant metastases decreased with age. Shorter period of
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surveillance due to reduced survival and less rigorous follow-up in the oldest patients might
be responsible for these findings, and no firm conclusion should be drawn. 
The overall five-year survival rates for patients undergoing curative major surgery in this
study are comparable to previous series on rectal cancer treatment in the elderly [15-17]. Due
to incomplete information on causes of death in this national study, relative survival in the
different age groups was evaluated. There were no significant differences in relative survival
between the age groups of patients treated for cure with major surgery, confirming that
selected elderly patients benefit from this treatment. Major rectal cancer surgery with TME
technique should not be restricted on the basis of high age alone. 
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Conclusion
In this series, evaluating a national cohort of rectal cancer patients, the relative survival
decreased with age. The results indicate that both the rate of surgical treatment and curative
resections decrease with age. Furthermore, the rate of restorative resections decreases, while
abdominoperineal resection and Hartmann’s procedure increase. Systematic preoperative
staging and a thorough evaluation concerning the general health of the patient are essential in
deciding the appropriate treatment of rectal cancer patients. Different treatment options
should be considered and the expected results of the alternative procedures assessed. To
accomplish an optimal treatment of old rectal cancer patients this process is of utmost
importance. Although similar chronological age, old patients as a group are heterogeneous,
and rigid treatment guidelines based on high age should be avoided. In selected patients,
major rectal resection with TME technique can be performed with similar rates of local
recurrence, distant metastasis and relative survival, irrespective of age.
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Table 1  Characteristics of 4875 Patients  65 Years of Age with Rectal Cancer within 16 cm from the Anal Verge
65 - 74 years 75 - 79 years 80 - 84 years  85 years
 n     (%)  n     (%) n     (%) n     (%) P
 2086  (43) 1223  (25) 949   (20) 617   (13)
Age, mean(range)   70(65-74)    77(75-79)     82(80-84)   88(85-105)
Gender < 0.001*
  Female    787   (38) 544   (45) 471   (50)  364   (59)
  Male  1299   (62) 679   (56) 478   (50)  253   (41)
Surgical Treatment < 0.001*
  Yes 1992   (96) 1142  (93) 848   (89) 479    (78)
  No    94    (5)    81    (7) 101   (11) 138    (22)
Curative Resection < 0.001*
  Yes 1598  (77) 882  (72) 624  (66) 290  (47)
  No 488  (23) 341  (28) 325  (34) 327 (53)
Surgical Procedure*** < 0.001**
Local treatment       75     (4)       64    (6)       74     (9)     67    (14)
  Palliative treatment      121    (6)      101   (9)       99    (12)   111    (23)
  AR    1147   (58)        567  (50)     365    (43)   139    (29)
  APR      498   (25)      294  (26)     202   (24)     88    (18)
  Hartmann      143     (7)      110  (10)     102   (12)     72    (15)
  Proctocolectomy         7     (0)          4   (0)        6     (1)       1     (0)
  Not given         1     (0)          2   (0)        0     (0)       1     (0)
Dukes' stage***
A  513    (26)  273   (24)  206   (24) 100    (21)  0.149*
  B 628    (32)  366    (32)  235   (28) 142    (30)  0.144*
  C  507    (26)  289    (25)  232   (27) 102    (21)  0.112*
  D  303    (15)  174    (15)   128   (15)  70    (15)  0.989*
  Not given  41      (2)   40     (4)   47    (6)  65    (14)
T-stage***
  T1   205    (10) 108   (10)   83   (10)  61   (13) 0.241*
  T2   430    (22) 238   (21) 182   (22)  82   (17) 0.181*
  T3 1051    (53) 594   (52) 426   (50) 212   (44) 0.008*
  T4   283    (14) 181   (16) 131   (15)  96   (20) 0.017*
  Not given   23     (1)   21    (2)  26     (3)  28     (6)
R-stage***
  R0  1453    (73)  783     (69)  544   (64) 249    (52) < 0.001*
  R1   145      (7)    99       (9)    80     (9)   41      (9)   0.223*
  R2   376    (19)   241     (21)  207   (24)  170     (36) < 0.001*
  Not given     18      (1)    19       (2)   17     (2)   19      (4)
  Pearson Chi-Square*
  Fisher Exact**
  Patients undergoing surgery***
  AR = anterior resection; APR = abdominoperineal resection
Table 2    Five-year Overall and Relative Survival According to Age Group, 4875 Patients  65 
                years of Age with Rectal Cancer within 16 cm from Anal Verge
   Age Group    No of Patients   Overall Survival Relative Survival
n %    95% CI*   p < 0.001** %    95% CI***  
   65 - 74 years 2086 51    49 - 54 60    58 - 63
   75 - 79 years 1223 38    35 - 41 53    49 - 57
   80 - 84 years 949 28    25 - 31 49    43 - 54
  85 years 617 14    11 - 17 36    29 - 44
   Total 4875 39    38 - 40
   * Kaplan-Meier, ** log rank test, *** Esteve 
Table 3  Characteristics of 2840 Patients  65 Years of Age treated 
              with Curative AR, APR or Hartmann's Procedure and TME Technique
65 - 74 years 75 - 79 years 80 - 84 years   85 years P
 n     (%) n     (%) n     (%)  n     (%)
1383  (49) 741  (26) 504   (18) 212   (8)
Age, mean(range) 70(65-74)   77(75-79)   82(80-84)   88(85-97)
Gender < 0.001*
  Female  514   (37) 321   (43) 236   (47)   118   (56)
  Male  868   (63) 420   (57) 268   (53)    94   (44)
Lower border (cm), mean(range) 8.7(0-16) 8.8(0-16) 8.5(0-16)   8.2(0-16) 0.190**
Tumor diameter (cm), mean(range) 4.3(0-12) 4.5(1-15) 4.7(0-20) 4.5(1-14) 0.001**
Differentiation
  G1 (high)   95     (7)  53     (7)    37     (7)    17     (8) 0.934*
  G2 (medium) 1079    (78) 586   (79)  386   (77)   167    (79) 0.764*
  G3 (low)   129    (9) 65   (9)  61   (12)    22    (10) 0.226*
  Not given  80    (6) 37    (5)  20     (4)     6      (3)
T-stage
  T1    135     (10) 52     (7) 32    (6)     7      (3) 0.002*
  T2   355     (26) 197   (27) 133   (26)   48     (23) 0.695*
  T3 777     (56) 432   (58) 300   (60)  143     (68) 0.017*
  T4   111     (8) 59   (8) 39   (8)   13     (6) 0.815*
  Not given     5       (0)  1     (0)  0     (0)    1     (0)
N-stage
  N0  951    (69) 495   (67) 313   (62)  137   (65) 0.049*
  N1   297    (22) 174   (24) 137   (27)   56   (26) 0.047*
  N2   133    (10) 71   (10) 54   (11)   19     (9) 0.867*
  Not given   2      (0)   1    (0)  0    (0)     0     (0)
Dukes' stadium
  A 420     (30) 206   (28) 140   (28) 41   (19) 0.010*
  B 527     (38) 288   (39) 173   (34) 95   (45) 0.064*
  C 431     (31) 245   (33) 190   (38) 75   (35) 0.054*
  Not given   5       (0)   2     (0)   0    (0) 1   (0)
Operative treatment < 0.001*
  AR    921   (67)   454   (61) 283   (56) 97   (46)
  APR 389   (28) 225   (30) 160   (32) 71   (34)
  Hartmann 73   (5) 62   (8) 61   (12) 44   (21)
R-stage 0.087*
  R0 1265   (92) 666  (90) 444   (88) 186   (88)
  R1    118     (9)   75  (10)   60    (12) 26   (12)
Preoperative radiotherapy < 0.001*
  Yes 111   (8) 43  (6) 12   (2) 5   (2)
  No 1272 (92) 698  (94) 492   (98) 207   (98)
Postoperative radiotherapy 0.001*
  Yes 76   (6) 31  (4) 13   (3) 1   (1)
  No 1307 (95) 710   (96) 491   (97) 211   (100)
Postoperative mortality (30 days) < 0.001*
  Yes 34   (3) 25   (3) 36   (7) 16   (8)
  No 1349 (98) 716   (97) 468   (93) 196   (93)
  Pearson Chi-Square*
  Oneway Anova**
Table 4  Five-year Local Recurrence, Metastasis, Overall Survival, Disease-free Survival and Relative Survival According to Age Group, 
             2840 Patients  65 years of Age treated with Curative AR, APR or Hartmann's Procedure and TME technique for Rectal Cance
   Age Group No of Patients    Local Recurrence       Metastasis   Overall Survival Disease-free Survival  Relative Survival
n  %     95% CI*   p = 0.315**   %      95% CI*   p = 0.244**  %       95% CI*   p < 0.001**  %      95% CI*   p < 0.001**  %      95% CI***
   65 - 74 years 1383   14     13 - 17    23     21 - 26         65     63 - 68         58     55 - 61         77     73 - 80     
   75 - 79 years 741   12     10 - 15    24     21 - 28   50     46 - 54   47     43 - 51   70     64 - 75
   80 - 84 years 504   14     10 - 18    23     18 - 28   41     36 - 46   39     34 - 43   72     63 - 79 
  85 years 212   17     10 - 24    17     10 - 23   25     18 - 32   24     18 - 31   65     44 - 79
   Total 2840   14     13 -16    23     21 - 25   54     52 - 56   49     48 - 51
   * Kaplan-Meier, ** log rank test, *** Esteve
Table 5 Factors influencing Local Recurrence, Metastasis and Overall Survival  after Curative APR, AR
             or Hartmann's Procedure with TME Technique in 2840 Patients with Rectal Cancer 
             Local Recurrence                  Metastasis               Overall Survival
Variable  HR            95% CI                P*  HR            95% CI                 P* HR        95% CI                   P*  
Gender                                             0.991                                              0.930                                          < 0.001
  Female   1              Reference   1             Reference    1             Reference
  Male   1.0           0.8 - 1.3   1.0           0.9 - 1.2   1.3           1.2 - 1.5
Age group                                             0.362                                              0.023                                           < 0.001
  65 - 74    1             Reference    1             Reference    1             Reference
  75 - 79   0.8           0.6 - 1.0   1.0           0.8 - 1.2   1.7           1.5 - 1.9
  80 - 84   0.9           0.7 - 1.3   0.8           0.6 - 1.1   2.2           1.9 - 2.6
  ≥ 85   0.9           0.6 - 1.4   0.5           0.4 - 0.8   2.8           2.3 - 3.4
Tumour level (mm)                                             0.061                                              0.560                                             0.061
  0 - 59   1.5           1.0 - 2.3   1.1           0.7 - 1.5   1.1           0.8 - 1.3
  60 - 119   1.4           1.0 - 1.8   1.1           0.9 - 1.4   1.2           1.0 - 1.3
 120 - 160   1              Reference    1             Reference    1             Reference
T - Stage                                           < 0.001                                            < 0.001                                           < 0.001
  T1   1              Reference    1             Reference    1             Reference
  T2   3.0           1.1 - 8.3   1.8           1.0 - 3.4   1.2           0.9 - 1.6
  T3   7.7           2.8 - 20.8   4.3           2.4 - 7.7   2.0           1.5 - 2.5
  T4 12.8           4.6 - 36.0   4.9           2.6 - 9.2   2.9           2.1 - 3.9
N - stage                                           < 0.001                                            < 0.001                                           < 0.001
  N0    1             Reference    1             Reference    1             Reference
  N1   1.5           1.2 - 2.0   2.1           1.7 - 2.5   1.5           1.3 - 1.7
  N2   2.7           2.0 - 3.7   4.3           3.4 - 5.4   2.4           2.0 - 2.8
Differentiation                                              0.075                                              0.019                                              0.009
  High    1             Reference    1             Reference    1             Reference
  Medium    1.7          0.9 - 3.2    0.8          0.5 - 1.1    1.0          0.8 - 1.2
  Low    2.2          1.1 - 4.4    1.1          0.7 - 1.6    1.3          1.0 - 1.7
R - stage                                              0.001                                           < 0.001                                           < 0.001
  R0    1             Reference    1             Reference    1             Reference
  R1    1.7          1.2 - 2.2    1.9          1.5 - 2.3    1.4          1.2 - 1.6
Operative treatment                                              0.202                                              0.121                                           < 0.001
  AR    1             Reference    1             Reference    1             Reference
  APR    1.1          0.7 - 1.6    1.4          1.1 - 1.8    1.3          1.1 - 1.5
  Hartmann    1.4          1.0 - 2.1    1.2          0.8 - 1.6    1.5          1.2 - 1.8 
AR = anterior resection; APR = abdominoperineal resection; TME = total mesorectal excisison; HR = hazard ratio; CI = confidence interval
* Cox regression
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Legends
Figure 1.      Relative survival by age group for all rectal cancer patients
Figure 2.      Relative survival by age group in patients with curative resection
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